Literature DB >> 21626228

High prevalence of cholelithiasis in primary hyperparathyroidism: a retrospective analysis of 120 cases.

Sanjay Kumar Bhadada, Anil Bhansali, Viral N Shah, A Behera, M Ravikiran, R Santosh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21626228     DOI： 10.1007/s12664-011-0101-0

Source DB:  PubMed          Journal:  Indian J Gastroenterol        ISSN： 0254-8860


× No keyword cloud information.
  9 in total

1.  Epidemiology of gallstone disease in Chandigarh: a community-based study.

Authors:  V Singh; B Trikha; C Nain; K Singh; S Bose
Journal:  J Gastroenterol Hepatol       Date:  2001-05       Impact factor: 4.029

Review 2.  Parathyroid hormone as a smooth muscle relaxant.

Authors:  L L Mok; G A Nickols; J C Thompson; C W Cooper
Journal:  Endocr Rev       Date:  1989-11       Impact factor: 19.871

3.  Analysis of 645 patients with primary hyperparathyroidism with special references to cholelithiasis.

Authors:  Petr Don Broulik; Tomas Haas; Svaiopiak Adámek
Journal:  Intern Med       Date:  2005-09       Impact factor: 1.271

4.  Primary hyperparathyroidism. Analysis of findings in a series of 129 patients.

Authors:  S Werner; B Hjern; H E Sjöberg
Journal:  Acta Chir Scand       Date:  1974

5.  Epidemiological study of cholelithiasis among railroad workers in India with special reference to causation.

Authors:  S L Malhotra
Journal:  Gut       Date:  1968-06       Impact factor: 23.059

6.  A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery.

Authors:  S J Silverberg; E Shane; T P Jacobs; E Siris; J P Bilezikian
Journal:  N Engl J Med       Date:  1999-10-21       Impact factor: 91.245

7.  Hypercalcemia decreases bile flow and increases biliary calcium in the prairie dog.

Authors:  S A Ahrendt; G M Ahrendt; H A Pitt; E W Moore; K D Lillemoe
Journal:  Surgery       Date:  1995-04       Impact factor: 3.982

8.  Persistent and recurrent sporadic primary hyperparathyroidism: histopathology, complications, and results of reoperation.

Authors:  C J Weber; C W Sewell; W C McGarity
Journal:  Surgery       Date:  1994-12       Impact factor: 3.982

9.  Primary hyperparathyroidism: changes in the pattern of clinical presentation.

Authors:  G R Mundy; D H Cove; R Fisken
Journal:  Lancet       Date:  1980-06-21       Impact factor: 79.321
  9 in total
  6 in total

1.  Chief cell and clear cell parathyroid adenoma do not influence clinical and biochemical expression of the sporadic primary hyperparathyroidism.

Authors:  Shweta Varshney; Sanjay Kumar Bhadada; Uma Nahar; Viral N Shah; Anil Bhansali; Arnanshu Behera
Journal:  Endocrine       Date:  2012-10-07       Impact factor: 3.633

2.  Pulmonary function tests in patients with primary hyperparathyroidism.

Authors:  Sanjay Kumar Bhadada; Ahutosh Agrawal; Viral N Shah; Anil Bhansali; Arnanshu Behera; Anish Bhattacharya; Uma Nahar
Journal:  Indian J Endocrinol Metab       Date:  2012-05

3.  Changes in clinical & biochemical presentations of primary hyperparathyroidism in India over a period of 20 years.

Authors:  Viral N Shah; Sanjay Bhadada; Anil Bhansali; Arnanshu Behera; B R Mittal
Journal:  Indian J Med Res       Date:  2014-05       Impact factor: 2.375

4.  Effect of gender, biochemical parameters & parathyroid surgery on gastrointestinal manifestations of symptomatic primary hyperparathyroidism.

Authors:  Viral N Shah; Sanjay Kumar Bhadada; Anil Bhansali; A Behera; Anish Bhattacharya; Uma Nahar; Deepak Bhasin; Bhavin Vadera
Journal:  Indian J Med Res       Date:  2014-02       Impact factor: 2.375

5.  Gallstones were associated with the gastrointestinal adverse events of cinacalcet in hemodialysis patients with secondary hyperparathyroidism.

Authors:  Keiichi Otsuka; Yoichi Ohno; Joji Oshima
Journal:  Ren Fail       Date:  2018-11       Impact factor: 2.606

6.  Clinical features and outcomes in 38 dogs with cholelithiasis receiving conservative or surgical management.

Authors:  Frederik Allan; Penny J Watson; Katie E McCallum
Journal:  J Vet Intern Med       Date:  2021-10-29       Impact factor: 3.333
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.